OppenheimerFunds’s Myriad Genetics MYGN Stock Holding History

OppenheimerFunds’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$493K	Buy	14,859 +2,034	+16%	+$61.9K	﹤0.01%	1373
2018 Q4	$373K	Buy	12,825 +2,100	+20%	+$75.5K	﹤0.01%	1484
2018 Q3	$493K	Sell	10,725 -1,579	-13%	-$70.2K	﹤0.01%	1455
2018 Q2	$460K	Sell	12,304 -4,194	-25%	-$142K	﹤0.01%	1457
2018 Q1	$488K	Buy	16,498 +60	+0.4%	+$2.03K	﹤0.01%	1411
2017 Q4	$564K	Sell	16,438 -604	-4%	-$20.4K	﹤0.01%	1452
2017 Q3	$616K	Sell	17,042 -8,133	-32%	-$232K	﹤0.01%	1424
2017 Q2	$651K	Sell	25,175 -4,996	-17%	-$106K	﹤0.01%	1380
2017 Q1	$579K	Buy	+30,171	New	+$535K	﹤0.01%	1443

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OppenheimerFunds's MYGN Position: Q1 2019 in Review

OppenheimerFunds increased its Myriad Genetics (MYGN) stake by 16% in Q1 2019, buying an estimated $61.9K and bringing the position to 14,859 shares worth $493K. The position accounts for ﹤0.01% of the portfolio, ranked #1373.

OppenheimerFunds first reported a position in MYGN in Q1 2017 and has held it in 9 quarters since. The position peaked at $651K in Q2 2017. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

OppenheimerFunds held 14,859 shares of Myriad Genetics worth $493K as of Q1 2019.
OppenheimerFunds bought 2,034 Myriad Genetics shares in Q1 2019, an estimated $61.9K.
Myriad Genetics made up ﹤0.01% of OppenheimerFunds's portfolio in Q1 2019, its #1373 holding.
OppenheimerFunds first reported a position in Myriad Genetics in Q1 2017 and has held it in 9 quarters since.
OppenheimerFunds's Myriad Genetics position peaked at $651K in Q2 2017.
262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.